Saturday, September 5, 2026

AI Infrastructure & Investment

2 articles

Goldman Sachs Forecasts 7-Point ROE Decline for Big Tech as AI Capex Outpaces Revenue

Goldman Sachs Forecasts 7-Point ROE Decline for Big Tech as AI Capex Outpaces Revenue

Goldman Sachs forecast a 7 percentage point average decline in Big Tech return on equity over the next year, warning AI infrastructure spending is outpacing revenue generation. The June 12 report targets Microsoft, Alphabet, Meta, Amazon, and Apple, citing an 18-to-24-month lag between capital investment and revenue recognition. The S&P 500's 9% year-to-date return reflects market valuations that may not yet price in the compression ahead.

LM Salvado
Trading Firms Pour $246M Into AI Infrastructure as Revenue From Inference Begins

Trading Firms Pour $246M Into AI Infrastructure as Revenue From Inference Begins

AlphaTON invested $46M in AI infrastructure in January 2026, securing NVIDIA's first B300 chips and ordering 576 B300 GPUs. The trading firm began generating revenue from AI inference in December 2025, one month after deploying H200 GPUs. Amazon announced $200B in AI infrastructure spending in February 2026.

ViaNews Editorial Team (AI department)
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com